{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04409080",
            "orgStudyIdInfo": {
                "id": "R7257-RAA-1947"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-002031-29",
                    "type": "EUDRACT_NUMBER"
                },
                {
                    "id": "2023-508601-24-00",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy",
            "officialTitle": "A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy",
            "therapeuticArea": [
                "Other"
            ],
            "study": "in-adult-patients-with-severe-aplastic-anemia-that-is-refractory-to-or-relapsed-on-immunosuppressive-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-01-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-05-26",
            "studyFirstSubmitQcDate": "2020-05-26",
            "studyFirstPostDateStruct": {
                "date": "2020-06-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is researching an experimental drug called REGN7257 (called \"study drug\"). The study is focused on patients who have severe aplastic anemia (SAA), a disease of the bone marrow resulting in an impairment of the production of blood cells.\n\nThe main purpose of this two-part study (Part A and Part B) is to test how safe and tolerable REGN7257 is in patients with SAA in which other Immunosuppressive therapies (ISTs) have not worked well.\n\nThe study is looking at several other research questions to better understand the following properties of REGN7257:\n\n* Side effects that may be experienced by participants taking REGN7257\n* How REGN7257 works in the body\n* How much REGN7257 is present in blood after dosing\n* If REGN7257 works to raise levels of certain blood counts after treatment\n* How quickly REGN7257 works to raise levels of certain blood counts\n* In patients for whom REGN7257 works to raise levels of certain blood counts after treatment, how many continue to show such a response throughout the study\n* If REGN7257 works to lower the number of platelet and red blood cell transfusions needed\n* How REGN7257 changes immune cell counts and composition\n* How the body reacts to REGN7257 and if it produces proteins that bind to REGN7257 (this would be called the formation of anti-drug antibodies \\[ADA\\])"
        },
        "conditionsModule": {
            "conditions": [
                "Severe Aplastic Anemia (SAA)"
            ],
            "keywords": [
                "Immunosuppressive therapy (IST)",
                "Refractory",
                "Relapsed"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 33,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A",
                    "type": "EXPERIMENTAL",
                    "description": "Part A: Single ascending dose (SAD) escalation cohorts",
                    "interventionNames": [
                        "Drug: REGN7257"
                    ]
                },
                {
                    "label": "Part B",
                    "type": "EXPERIMENTAL",
                    "description": "Part B: Multiple REGN7257 dosages.",
                    "interventionNames": [
                        "Drug: REGN7257"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "REGN7257",
                    "description": "Administered by intravenous (IV) infusion, in Part A and B.",
                    "armGroupLabels": [
                        "Part A",
                        "Part B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs)",
                    "description": "Part A",
                    "timeFrame": "12 months post-treatment, approximately 52 weeks"
                },
                {
                    "measure": "Incidence of serious adverse events (SAEs)",
                    "description": "Part A",
                    "timeFrame": "12 months post-treatment, approximately 52 weeks"
                },
                {
                    "measure": "Incidence and severity of treatment-emergent adverse events (TEAEs)",
                    "description": "Part A",
                    "timeFrame": "12 months post-treatment, approximately 52 weeks"
                },
                {
                    "measure": "Incidence of serious adverse events (SAEs)",
                    "description": "Part B",
                    "timeFrame": "Through the end of study visit, approximately 78 weeks"
                },
                {
                    "measure": "Incidence and severity of treatment-emergent adverse events (TEAEs)",
                    "description": "Part B",
                    "timeFrame": "Through the end of study visit, approximately 78 weeks"
                },
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Part B",
                    "timeFrame": "At 6 months, approximately 26 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "ORR",
                    "description": "Parts A and B",
                    "timeFrame": "At 3 months, approximately 12 weeks"
                },
                {
                    "measure": "Complete response (CR)",
                    "description": "Parts A and B",
                    "timeFrame": "At 3 months, approximately 12 weeks"
                },
                {
                    "measure": "Partial response (PR)",
                    "description": "Parts A and B",
                    "timeFrame": "At 3 months, approximately 12 weeks"
                },
                {
                    "measure": "Time to best response",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Time to best response",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Time to first response",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Time to first response",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Any clinical response",
                    "description": "Part A",
                    "timeFrame": "Until the end of study, approximately week 52"
                },
                {
                    "measure": "Any clinical response",
                    "description": "Part B",
                    "timeFrame": "Until the end of study, approximately week 78"
                },
                {
                    "measure": "Platelet transfusions per month over time",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Platelet transfusions per month over time",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Red blood cell transfusions per month over time",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Red blood cell transfusions per month over time",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in lymphocyte cell counts",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in lymphocyte cell counts",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in neutrophil cell counts",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in neutrophil cell counts",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in hemoglobin cell counts",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in hemoglobin cell counts",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in reticulocyte cell counts",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in reticulocyte cell counts",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in platelet cell counts",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in platelet cell counts",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in the whole blood immune cell subsets (T cells)",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in the whole blood immune cell subsets (T cells)",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in the whole blood immune cell subsets (B cells)",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in the whole blood immune cell subsets (B cells)",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Changes in the whole blood immune cell subsets [Natural killer (NK) cells]",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Changes in the whole blood immune cell subsets (NK cells)",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Drug concentrations in serum over time",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Drug concentrations in serum over time",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Incidence of treatment-emergent anti-drug antibody (ADA) over time",
                    "description": "Part A",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Incidence of treatment-emergent ADA over time",
                    "description": "Part B",
                    "timeFrame": "Up to 18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Part A: SAA that is IST-refractory or IST-relapsed, as defined in the protocol\n2. Part B: SAA that is IST-relapsed, as defined in the protocol\n3. Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a treatment option or has been refused by the patient\n4. Adequate hepatic and renal function as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Diagnosis of Fanconi anemia or other congenital bone marrow failure syndrome as defined in the protocol\n2. Evidence of myelodysplastic syndrome as defined in the protocol\n3. Paroxysmal nocturnal hemoglobinuria (PNH) with evidence of clinically significant hemolysis (eg, treatment indicated) or history of PNH-associated thrombosis\n4. Treatment with a T cell-depleting agent (eg, ATG or alemtuzumab) within 6 months prior to dosing\n5. Treatment with a calcineurin inhibitor (eg, cyclosporine) within 4 weeks prior to dosing for patients enrolled in Part A\n6. Treatment with eltrombopag or investigational thrombopoietin receptor agonist, Granulocyte Colony-Stimulating Factor (G-CSF), or an androgen (eg, danazol), within 2 weeks prior to dosing\n7. HIV, hepatitis B or hepatitis C positive by serological testing at the screening visit as defined in the protocol\n8. Active tuberculosis, latent tuberculosis infection (LTBI) or history incompletely-treated tuberculosis or LTBI\n9. Active infection as defined in the protocol\n\nNote: Other protocol-defined inclusion/ exclusion criteria apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "844-734-6643",
                    "email": "clinicaltrials@regeneron.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Management",
                    "affiliation": "Regeneron Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cleveland Clinic Foundation",
                    "status": "COMPLETED",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tapan Kadia",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Hopital Saint-Louis - APHP",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "state": "Ile-de-France",
                    "zip": "75010",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Regis Peffault de Latour",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Gachon University Gil Hospital",
                    "status": "RECRUITING",
                    "city": "Incheon",
                    "state": "Gyeonggi",
                    "zip": "21565",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Hawk Kim",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.45646,
                        "lon": 126.70515
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Capital Area",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Sung Soo Yoon",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Capital Area",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Jun Ho Jang",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "The Catholic University of Korea, Seoul St. Marys Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Capital Area",
                    "zip": "06591",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Jong Wook Lee",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Ewha Womans University Medical Centre",
                    "status": "COMPLETED",
                    "city": "Seoul",
                    "state": "Seoul Capital Area",
                    "zip": "07985",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "St James's University Hospital",
                    "status": "RECRUITING",
                    "city": "Leeds",
                    "state": "West Yorkshire",
                    "zip": "LS97TF",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Morag Griffin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.79648,
                        "lon": -1.54785
                    }
                },
                {
                    "facility": "King's College Hospital, London",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "SE5 9RS",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Austin Kulasekararaj",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.",
            "accessCriteria": "Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency \\[EMA\\], Pharmaceuticals and Medical Devices Agency \\[PMDA\\], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000000741",
                    "term": "Anemia, Aplastic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000080983",
                    "term": "Bone Marrow Failure Disorders"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "asFound": "Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4071",
                    "name": "Anemia, Aplastic",
                    "asFound": "Aplastic Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18908",
                    "name": "Severe Combined Immunodeficiency",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2241",
                    "name": "Bone Marrow Failure Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M13118",
                    "name": "Pancytopenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T460",
                    "name": "Aplastic Anemia",
                    "asFound": "Aplastic Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5187",
                    "name": "Severe Combined Immunodeficiency",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M10411",
                    "name": "Interleukin-2",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}